Breaking genetic shackles: The advance of base editing in genetic disorder treatment
F Xu, C Zheng, W Xu, S Zhang, S Liu… - Frontiers in …, 2024 - frontiersin.org
The rapid evolution of gene editing technology has markedly improved the outlook for
treating genetic diseases. Base editing, recognized as an exceptionally precise genetic …
treating genetic diseases. Base editing, recognized as an exceptionally precise genetic …
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?
Abstract Purpose of Review Atherosclerotic cardiovascular disease (ASCVD) is a leading
cause of premature death. Lipid disorders, particularly elevated serum low-density …
cause of premature death. Lipid disorders, particularly elevated serum low-density …
Lipid Disorders and Pregnancy
D Schatoff, IY Jung, IJ Goldberg - … and Metabolism Clinics, 2024 - endo.theclinics.com
Lipid disorders occasionally complicate infertility treatments and the course of a pregnancy
and affect the use of medications during lactation. The most dramatic situation is the …
and affect the use of medications during lactation. The most dramatic situation is the …
[HTML][HTML] The impact of PCSK9 gene polymorphisms on ischemic stroke: a systematic review and Meta-analysis
J Wang, S Li, Y Ren, G Wang, W Li - Journal of Integrative …, 2024 - imrpress.com
Background: Single-nucleotide polymorphisms (SNPs) in the proprotein convertase
subtilisin/kexin type 9 (PCSK9) gene are known to be associated with susceptibility to …
subtilisin/kexin type 9 (PCSK9) gene are known to be associated with susceptibility to …
The Intersection of Genetic Factors, Aberrant Nutrient Metabolism and Oxidative Stress in the Progression of Cardiometabolic Disease
AJ Butcko, AK Putman, EP Mottillo - Antioxidants, 2024 - mdpi.com
Cardiometabolic disease (CMD), which encompasses metabolic-associated fatty liver
disease (MAFLD), chronic kidney disease (CKD) and cardiovascular disease (CVD), has …
disease (MAFLD), chronic kidney disease (CKD) and cardiovascular disease (CVD), has …
Targeting Allosteric Site of PCSK9 Enzyme for the Identification of Small Molecule Inhibitors: An In Silico Drug Repurposing Study
The primary cause of atherosclerotic cardiovascular disease (ASCVD) is elevated levels of
low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 …
low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 …
Drug development advances in human genetics‐based targets
X Zhang, W Yu, Y Li, A Wang, H Cao, Y Fu - MedComm, 2024 - Wiley Online Library
Drug development is a long and costly process, with a high degree of uncertainty from the
identification of a drug target to its market launch. Targeted drugs supported by human …
identification of a drug target to its market launch. Targeted drugs supported by human …
Advances in Molecular Biotechnology for Diagnosing and Treating Familial Hypercholesterolemia
S ZHANG, L ZHANG, Y ZHANG, J LI - Chinese General Practice, 2024 - chinagp.net
Familial hypercholesterolemia (FH) is an inherited disorder of lipid metabolism
characterized by significant elevation of low-density lipoprotein cholesterol, increasing the …
characterized by significant elevation of low-density lipoprotein cholesterol, increasing the …